Neurology
NeuroSense partners with PhaseV on upcoming phase 3 ALS trial
May 16, 2024Research and Development NeuroSense, Neurology, als, clinical trials
NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
Broken String Biosciences and the Francis Crick Institute collaborate on ALS research
May 7, 2024Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics
Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …
Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder
April 22, 2024Research and Development Kaerus Bioscience, Neurolentech, Neurology, neurodevelopmental disorders, neurology
Neurolentech has announced that it has entered into a technology access partnership with Kaerus Bioscience, with the aim of driving …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
April 17, 2024Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
PureTech Health launches Seaport Therapeutics
April 9, 2024Business Services Financing, Neurology, PureTech Health, launch
PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
March 25, 2024Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
March 21, 2024Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …
Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
February 28, 2024Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …
Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
February 21, 2024Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment
February 20, 2024Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA
argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …
Regenxbio announces positive data from trial for MPS II treatment
February 8, 2024Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial
Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …
Vivet Therapeutics gains €4.9m for gene therapy development
February 2, 2024Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy
Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …
FDA clears Aruna Bio’s IND for AB126 to enter clinical trials
January 17, 2024Research and Development Aruna Bio, FDA, IND, Neurology, clinical trials
Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
